Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Guanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.44 |
| ▸ | PNP | P00491 | 2/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.47 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanine SCHEMBL76056 | 1.00 | PNP (0.84) | PNPALDH1A1KDM4EMEN1MAPT | |
| Guanine SCHEMBL101895 | 1.00 | PNP (0.84) | PNPALDH1A1KDM4EMEN1MAPT | |
| Guanine SCHEMBL27448636 | 0.97 | PNP (0.79) | PNPALDH1A1KDM4EMEN1MAPT | |
| Guanine SCHEMBL27619007 | 0.95 | PNP (0.77) | PNPALDH1A1KDM4EMEN1MAPT | |
| Guanine SCHEMBL28445236 | 0.95 | PNP (0.77) | PNPALDH1A1KDM4EMEN1MAPT | |
| Guanine SCHEMBL5372458 | 0.95 | PNP (0.81) | PNPALDH1A1KDM4EMEN1MAPT | |
| Guanine SCHEMBL28840730 | 0.94 | PNP (0.79) | PNPALDH1A1KDM4EMEN1MAPT | |
| Guanine SCHEMBL27947876 | 0.92 | PNP (0.77) | PNPALDH1A1KDM4EMEN1MAPT | |
| Guanine SCHEMBL7255284 | 0.92 | PNP (0.81) | PNPALDH1A1KDM4EMEN1MAPT | |
| Guanine SCHEMBL1264884 | 0.92 | PNP (1.00) | PNPALDH1A1KDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 570 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186477-A1 | COMPOSITIONS COMPRISING FLUDARABINE PHOSPHATE AND METHODS OF MAKING AND USING SAME TO TREAT CANCER | Areva Pharmaceuticals Limited (IE) | 2025-06-12 | — | — | US | claimed |
| WO-2025076039-A1 | CHLAMYDIAL PROTEASE-LIKE ACTIVITY FACTOR AND ADJUVANT COMPOSITIONS AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2025-04-10 | — | — | WO | claimed |
| WO-2025024670-A1 | SYSTEMS AND METHODS FOR METHYLATION ANALYSIS OF LIVER DISEASE | ACTIVE GENOMES EXPRESSED DIAGNOSTICS CORP (US) | 2025-01-30 | — | — | WO | claimed |
| CN-119101639-A | Genetically engineered bacterium for synthesizing fucosyllactose, and preparation method and application thereof | 汤臣倍健股份有限公司 | 2024-12-10 | — | — | CN | claimed |
| WO-2024152052-A1 | COMPOSITIONS COMPRISING FLUDARABINE PHOSPHATE AND METHODS OF MAKING AND USING SAME TO TREAT CANCER | AREVA PHARMACEUTICALS INC. (US) | 2024-07-18 | — | — | WO | claimed |
| CN-116144720-B | Method for producing pseudouridine by enzyme method | 苏州华赛生物工程技术有限公司 | 2024-05-28 | — | — | CN | claimed |
| US-11859180-B2 | Antisense oligonucleotide compositions | IONIS PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | claimed |
| CN-117083290-A | Hepatitis E virus-like particles and uses thereof | 港大科桥有限公司 | 2023-11-17 | — | — | CN | claimed |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | claimed |
| CN-116392604-A | Natural immune activation nano-drug, preparation method and application | 上海市肿瘤研究所 | 2023-07-07 | — | — | CN | claimed |
| US-20140329699-A1 | SYSTEMS AND METHODS FOR HIGH EFFICIENCY ELECTRONIC SEQUENCING AND DETECTION | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2014-11-06 | — | — | US | claimed |
| CN-104105797-A | System and method for efficient electronic sequencing and detection | GENAPSYS INC | 2014-10-15 | — | — | CN | claimed |
| EP-2785868-A1 | SYSTEMS AND METHODS FOR HIGH EFFICIENCY ELECTRONIC SEQUENCING AND DETECTION | Genapsys Inc. (US) | 2014-10-08 | — | — | EP | claimed |
| CN-103717753-A | System and method for genetic and biological analysis | GENAPSYS INC | 2014-04-09 | — | — | CN | claimed |
| WO-2013173789-A2 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS | ISIS PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | WO | claimed |
| WO-2013082619-A1 | SYSTEMS AND METHODS FOR HIGH EFFICIENCY ELECTRONIC SEQUENCING AND DETECTION | GENAPSYS, INC. (US) | 2013-06-06 | — | — | WO | claimed |
| WO-2012166742-A2 | SYSTEMS AND METHODS FOR GENETIC AND BIOLOGICAL ANALYSIS | GENAPSYS, INC. (US) | 2012-12-06 | — | — | WO | claimed |
| US-8173620-B2 | BHQ-caged nucleotide probes photolysable by two-photon excitation | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-05-08 | — | — | US | claimed |
| US-20100048502-A1 | BHQ-CAGED NUCLEOTIDE PROBES PHOTOLYSABLE BY TWO-PHOTON EXCITATION | NATIONAL SCIENCE FOUNDATION | 2010-02-25 | — | — | US | claimed |
| CN-101495504-A | Materials and methods for the generation of fully 2'-modified nucleic acid transcripts | ARCHEMIX CORP (US) | 2009-07-29 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11859180-B2 | Antisense oligonucleotide compositions | UPF1, SNRPA1, HNRNPA1 | DPP4 2034/4885PNP 213/4885ALDH1A1 2215/4885 |
| US-20100048502-A1 | BHQ-CAGED NUCLEOTIDE PROBES PHOTOLYSABLE BY TWO-PHOTON EXCITATION | NUDT1, RECQL, PNP | DPP4 2265/4885PNP 3/4885ALDH1A1 1338/4885 |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RTCB, HNRNPA1, HNRNPAB | DPP4 4587/4885PNP 2635/4885ALDH1A1 4484/4885 |
| US-20250186477-A1 | COMPOSITIONS COMPRISING FLUDARABINE PHOSPHATE AND METHODS OF MAKING AND USING SAME TO TREAT CANCER | BCL9, PAICS, CDA | DPP4 4570/4885PNP 30/4885ALDH1A1 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.